updated Fri. August 9, 2024
-
The Ledger Gazette
February 8, 2018
Eli Lilly and logo Strs Ohio cut its holdings in Eli Lilly and Co (NYSE:LLY) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 690,292 shares of the company's stock after selling 14,673 shares during the quarter. Strs OhioÃÂ ...
Life Sciences Intellectual Property Review
February 8, 2018
Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”. The lawsuit, filed at US District Court for the District of Massachusetts, claimed that Teva's affiliate company Labrys Biologics had made a major breakthrough in the research of migraineÃÂ ...
FiercePharma
February 7, 2018
MannKind, which continues to try to convince the market of the value of its inhaled insulin, has enticed a top scientific executive away from Eli Lilly as it explores new areas for the fast-acting drug. The Westlake Village, California-based company Tuesday announced that David Kendall, M.D., has joined asÃÂ ...
Labiotech.eu (blog)
February 7, 2018
Adocia is unhappy with Eli Lilly, which walked away from their diabetes collaborations, which has left the biotech without a Phase III partner. Not long ago, they were working together to produce new diabetes treatments but now the relationship between French biotech Adocia and big pharma Eli LillyÃÂ ...
Seeking Alpha
February 2, 2018
Eli Lilly (LLY) ended 2017 on a solid note, but it is the cautious guidance for 2018 which is a real showstopper. Sales growth is seen at just 1-3% despite the fact that some of the dollar weakness is accounted for in the projection. This makes me cautious, given that the company really seemed to make a turnÃÂ ...
Market Realist
January 31, 2018
Wall Street analysts estimate an ~3.1% increase in Eli Lilly & Co.'s (LLY) 4Q17 revenues to ~$5.9 billion. This increase follows the strong performance of several existing products as well as new products. Eli Lilly's products are sold in more than 120 countries, and its international sales contribute ~45.0% ofÃÂ ...
Nasdaq
January 31, 2018
(RTTNews.com) - Eli Lilly And Co. ( LLY ) revealed earnings for its fourth quarter that climbed compared to the same period last year. The company said its bottom line totaled $1.21 billion, or $1.14 per share. This was up from $1.01 billion, or $0.95 per share, in last year's fourth quarter. Analysts hadÃÂ ...
CNBC
January 31, 2018
Eli Lilly shares slid 5 percent on Wednesday over concerns about its animal health unit and pricing in the diabetes care market. The animal health segment's fourth-quarter revenue decreased 6 percent from the year earlier. Lilly CEO Dave Ricks told analysts the company expects slightly negative growth inÃÂ ...
Endpoints News
January 25, 2018
Eli Lilly $LLY had hoped that EXPEDITION3 would prove to the world that amyloid beta was the cause of Alzheimer's and that solanezumab could bend the curve of cognitive decline back to patients' favor — or at least for patients with an early-stage, mild form of the disease. Instead, the landmark failureÃÂ ...
Investorplace.com
January 25, 2018
Eli Lilly received Food and Drug Administration approval for Elanco, its flea and tick treatment on dogs. Given the trend in pet spending, this should be seen as a positive development for Eli Lilly stock. Further, there was positive data found in a clinical 1b trial when combed Lilly's Cyramza with Oraxol,ÃÂ ...
Indianapolis Star
January 25, 2018
WASHINGTON — The Senate on Wednesday voted 55-43 to confirm as Health and Human Services secretary Alex Azar, a former Eli Lilly and Co. executive who has said lowering drug prices will be his top priority. Azar held top positions at HHS under the George W. Bush administration before working forÃÂ ...
StockNewsJournal
January 23, 2018
Eli Lilly and Company (NYSE:LLY) market capitalization at present is $94.50B at the rate of $85.49 a share. The firm's price-to-sales ratio was noted 4.19 in contrast with an overall industry average of 4.11. Most of the active traders and investors are keen to find ways to compare the value of stocks.
GuruFocus.com
January 23, 2018
Investment company Clear Investment Research, Llc buys Eli Lilly and Co, sells Graphic Packaging Holding Co, iShares 1-3 Year Treasury Bond ETF, ACCO Brands Corp, Aon PLC during the 3-months ended 2017-12-31, according to the most recent filings of the investment company, Clear InvestmentÃÂ ...
Nasdaq
January 23, 2018
(RTTNews.com) - Elanco Animal Health, a division of Eli Lilly and Company ( LLY ), announced the approval of Credelio (lotilaner), a new monthly oral tick and flea treatment for dogs. The new option contains the patented active ingredient lotilaner, which targets the nervous system receptors of ticks andÃÂ ...
Benzinga
January 23, 2018
Trulicity accounts for around 40 percent of Eli Lilly's sales growth through 2021 based on current expectations, Divan said. A "triple threat" of headwinds is likely flying under the radar, including competition from Novo's Victoza after its recent label expansion, competition from Novo's once-weekly OzempicÃÂ ...
Motley Fool
January 22, 2018
What about Eli Lilly? The big pharma company does have its own set of challenges. Lilly's top-selling product, Humalog, has already lost patent exclusivity and will likely experience sales declines in the near future. Sales are already slipping for the company's No. 2 and No. 3 moneymakers, Cialis andÃÂ ...
Benzinga
January 21, 2018
The markets again are hitting new all-time highs, even with the bull nearly nine years old and the squabbling in Washington at a fever pitch. And as it does every week, Benzinga continues to feature looks at the prospects for many investor favorite stocks. Here are just a few of this past week's bullish andÃÂ ...
Motley Fool
January 17, 2018
Some could look at Eli Lilly and Company's (NYSE:LLY) stock gain of 15% in 2017 and think it was disappointing. After all, the S&P 500 index jumped 19% last year. Some of Lilly's peers performed even better than that. Others might be happy with Lilly's 2017 return, noting that it was much better than theÃÂ ...
Motley Fool
January 10, 2018
One year ago, Dave Ricks made his first appearance at the annual J.P. Morgan Healthcare Conference as CEO of Eli Lilly & Co. (NYSE:LLY). Lilly was coming off of a dismal stock performance in 2016, with shares falling close to 13%. Ricks spoke for the second time at the J.P. Morgan conference onÃÂ ...
The Ledger Gazette
January 2, 2018
Eli Lilly and logo Canada Pension Plan Investment Board lifted its stake in shares of Eli Lilly and Co (NYSE:LLY) by 6.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,173,534 shares of the company's stock afterÃÂ ...
Mondaq News Alerts
January 2, 2018
We have already reported on the Supreme Court's decision in Actavis v Eli Lilly (see here) which, as stated, is the most important decision in the last decade regarding patent infringement. However, it did also raise many questions, particularly as it was a decision that only considered the issue ofÃÂ ...
Frisco Fastball
January 2, 2018
Investors sentiment decreased to 0.89 in Q3 2017. Its down 0.01, from 0.9 in 2017Q2. It turned negative, as 66 investors sold Eli Lilly and Company shares while 386 reduced holdings. 79 funds opened positions while 325 raised stakes. 827.83 million shares or 0.59% more from 823.00 million shares inÃÂ ...
Market Realist
December 30, 2017
Eli Lilly and Company (LLY) is a US-based pharmaceutical company that manufactures human pharmaceuticals and animal health products. It's headquartered in Indianapolis, Indiana. The company surpassed analysts' estimates for EPS (earnings per share) and revenues, reporting EPS of $1.05 andÃÂ ...
Motley Fool
December 22, 2017
If AbbVie (NYSE:ABBV) and Eli Lilly (NYSE:LLY) stocks were in a horse race in 2017, Lilly would have been ahead for most of the first half of the race. Over the summer, AbbVie would have pulled ahead by a nose. But by September, Lilly would have fallen well behind, with AbbVie kicking dust in its face.
Benzinga
December 14, 2017
Eli Lilly and Company LLY issued financial guidance for 2018, which was in line with market expectations. The company also re-affirmed the previously issued 2017 projection as well as its long-term expectations. Shares were up more than 1% in Wednesday. So far this year, Lilly's share price has risenÃÂ ...
Seeking Alpha
December 13, 2017
Thanks for joining us for Eli Lilly and Company's conference call to discuss our 2018 financial guidance. I'm Dave Ricks, Lilly's Chairman and CEO. And joining me on today's call are Josh Smiley, currently our Treasurer, who'll become CFO on January 1st; Dr. Jan Lundberg, President of Lilly ResearchÃÂ ...
CNBC
December 13, 2017
Eli Lilly forecast 2018 earnings and revenue largely above estimates in part due to strong demand for diabetes drug Trulicity and psoriasis drug Taltz. The company said it expected 2018 revenue of $23.0 billion to $23.5 billion and adjusted earnings of $4.60 to $4.70 per share. Analysts on average wereÃÂ ...
Endpoints News
December 11, 2017
Sanofi $SNY got the greenlight from FDA to sell its me-too insulin product Admelog, threatening market leader Eli Lilly's $LLY blockbuster sales in diabetes. Admelog, a short-acting insulin lispro injection, is a follow-on product approved through an abbreviated pathway under the FDA's Federal Food, Drug,ÃÂ ...
Benzinga
December 31, 1999
The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs.
Barron's
December 31, 1999
As for Eli Lilly, Goldman Sachs' Jami Rubin and her team downgraded the stock from Buy to Neutral, writing that while they are still bullish on the company's long term, they're concerned that the bull thesis is well understood and already reflected in the stock's valuation. Moreover, Rubin argues, the risk toÃÂ ...
Endpoints News
December 6, 2017
Juno Therapeutics $JUNO is adding a new approach to its BCMA strategy for multiple myeloma after forging an in-licensing deal through a trio of alliances that includes Eli Lilly. Lilly is handing over rights on LY3039478 to Juno so it can use their gamma secretase inhibitor in the biotech's drive to leapfrog ...
StreetInsider.com
December 5, 2017
Yesterday marked dosing of the first patient with type 1 diabetes in a feasibility study to evaluate the functionality and safety of an automated insulin delivery (AID) system in development by Eli Lilly and Company (NYSE: LLY). The AID system is part of the Connected Diabetes Ecosystem, which is being ...
Endpoints News
December 5, 2017
In doing so, Novo also came up with superior data to Eli Lilly's Trulicity, setting up a head-to-head showdown that could cost Lilly dearly. Researchers also came up with some troubling instances of diabetic retinopathy, which can lead to blindness. But a near unanimous vote by a group of outside experts at ...
FiercePharma
December 4, 2017
Eli Lilly hopes some data on specific patient groups will help Taltz compete with Novartis' Cosentyx in psoriatic arthritis. Share Facebook Twitter LinkedIn Email Print. Eli Lilly's Taltz officially has a new arena where it can challenge Novartis' Cosentyx. On Friday, the FDA granted the immunology drug a ...
Motley Fool
November 27, 2017
At its recently knocked-down price, Merck shares offer a nice 3.5% yield that's far more tempting than the 2.5% yield Eli Lilly stock would provide at recent prices. Merck began raising its payout in 2012 after a years-long freeze, and Lilly did the same beginning in 2015. While you might be tempted to jump ...
The Ledger Gazette
November 26, 2017
Eli Lilly and logo New York State Common Retirement Fund boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.3%Â ...
New York Times
November 26, 2017
Democratic senators say that, as a top manager at Eli Lilly and Company, he was responsible for steep increases on insulin and other drugs.
Investorplace.com
November 24, 2017
The current recommendation of Buy for Eli Lilly and Company (NYSE:LLY) is the result of using Louis Navellier's Portfolio Grader stock ...
Xconomy
November 17, 2017
A cancer drug that Eli Lilly was positioning as a challenger to similar drugs from rivals Pfizer and Novartis has failed a late-stage clinical trial in ...
Politico
November 14, 2017
But the record of the former top executive for Eli Lilly, which tripled the price of a top-selling insulin drug while he led its U.S. operation, ...
Slate Magazine (blog)
November 14, 2017
Trump Health Secretary Nominee Left Job Overseeing Eli Lilly Investigation to Become Eli Lilly's Top Lobbyist ...
New York Times
November 13, 2017
Mr. Trump announced his choice of Alex M. Azar II, a former president of the American division of Eli Lilly and a health official in the George W.
Moneyshow.com
November 13, 2017
Eli Lilly and Company (LLY) was founded in 1876 and is headquartered in Indianapolis; If you want solidity and stability in your investments, ...
MedCity News
November 11, 2017
It just wouldn't feel like a Friday without some Trump cabinet intrigue so with that in mind, Alex Azar, the former president of Lilly's U.S. business ...
Seeking Alpha
November 7, 2017
There is a clear demonstration of the rich revenue source that Eli Lilly & Company showcases in comparison to companies such as Celgene.
Patch.com
November 6, 2017
INDIANAPOLIS, IN — More than a month after Eli Lilly and Co. announced it would cut 2,500 U.S. jobs by the end of the year, more than 2,300Â ...
StockNewsGazette
November 2, 2017
Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are the two most active stocks in the Drug Manufacturers ...
TrueBlueTribune
November 2, 2017
Eli Lilly and logo Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings results on Tuesday, October 24th. The company reported ...
StockNewsJournal
November 1, 2017
Eli Lilly and Company (NYSE:LLY) plunged -0.86% with the closing price of $81.94. The overall volume in the last trading session was 3.85Â ...
Life Sciences Intellectual Property Review
November 1, 2017
Three judges said today, November 1, that a patent directed to Eli Lilly's erectile dysfunction drug should have been found invalid for ...
|
news and opinion
|
